Loading...
XHELBIOBV
Market cap36mUSD
Dec 23, Last price  
2.33EUR
1D
0.87%
1Q
9.39%
Jan 2017
-61.49%
Name

Biohit Oyj

Chart & Performance

D1W1MN
XHEL:BIOBV chart
P/E
18.87
P/S
2.67
EPS
0.12
Div Yield, %
0.00%
Shrs. gr., 5y
0.15%
Rev. gr., 5y
5.66%
Revenues
13m
+19.40%
26,702,00028,660,00031,408,00032,751,00034,805,00035,366,00040,044,00039,922,0002,048,0003,452,0004,363,0006,051,0008,195,0008,979,0009,931,00010,052,0007,123,0009,361,00010,951,00013,076,000
Net income
2m
+207.99%
-169,000-226,000-839,000-1,502,000897,000387,00061,00037,710,000-3,656,000-5,917,000-1,161,000-2,917,000-3,295,0006,139,000-2,143,000-1,416,000-3,312,000-1,500,000601,0001,851,000
CFO
902k
-51.19%
2,238,000605,000100,0001,040,0001,188,0002,796,0001,961,0004,957,000-8,890,000-4,443,000-3,435,000-3,147,000-2,457,000-943,000-93,00083,000-25,000-444,0001,848,000902,000
Dividend
Apr 15, 20140.7234 EUR/sh
Earnings
Jun 05, 2025

Profile

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.
URL
https://www.biohithealthcare.com/
IPO date
Jun 18, 1999
Employees
42
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
13,076
19.40%
10,951
16.99%
9,361
31.42%
Cost of revenue
10,052
6,534
6,366
Unusual Expense (Income)
NOPBT
3,024
4,417
2,995
NOPBT Margin
23.13%
40.33%
31.99%
Operating Taxes
344
267
195
Tax Rate
11.38%
6.04%
6.51%
NOPAT
2,680
4,150
2,800
Net income
1,851
207.99%
601
-140.07%
(1,500)
-54.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
68
BB yield
-0.24%
Debt
Debt current
275
257
66
Long-term debt
1,129
1,629
376
Deferred revenue
Other long-term liabilities
7
7
7
Net debt
(5,528)
(294)
(718)
Cash flow
Cash from operating activities
902
1,848
(444)
CAPEX
(248)
(59)
(33)
Cash from investing activities
192
(625)
760
Cash from financing activities
(199)
(186)
(266)
FCF
1,752
3,482
2,619
Balance
Cash
6,814
6,227
5,515
Long term investments
118
(4,047)
(4,355)
Excess cash
6,278
1,632
692
Stockholders' equity
9,425
7,457
7,300
Invested Capital
3,856
6,636
6,655
ROIC
51.09%
62.45%
37.40%
ROCE
29.83%
53.40%
40.75%
EV
Common stock shares outstanding
15,127
15,065
15,046
Price
1.89
20.38%
1.57
-14.44%
1.84
-26.01%
Market cap
28,591
20.88%
23,653
-14.33%
27,609
-26.01%
EV
23,063
23,359
26,891
EBITDA
3,387
4,897
4,984
EV/EBITDA
6.81
4.77
5.40
Interest
223
34
9
Interest/NOPBT
7.37%
0.77%
0.30%